216 related articles for article (PubMed ID: 30482643)
1. Persistent negative symptoms in individuals at Ultra High Risk for psychosis.
Yung AR; Nelson B; McGorry PD; Wood SJ; Lin A
Schizophr Res; 2019 Apr; 206():355-361. PubMed ID: 30482643
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
[TBL] [Abstract][Full Text] [Related]
3. Identifying neurocognitive markers for outcome prediction of global functioning in individuals with first-episode and ultra-high-risk for psychosis.
Sawada K; Kanehara A; Sakakibara E; Eguchi S; Tada M; Satomura Y; Suga M; Koike S; Kasai K
Psychiatry Clin Neurosci; 2017 May; 71(5):318-327. PubMed ID: 28294477
[TBL] [Abstract][Full Text] [Related]
4. Persistent negative symptoms after first episode schizophrenia: A 2-year follow-up study.
Üçok A; Ergül C
Schizophr Res; 2014 Sep; 158(1-3):241-6. PubMed ID: 25107850
[TBL] [Abstract][Full Text] [Related]
5. Persistent Negative Symptoms in First-Episode Psychosis: Early Cognitive and Social Functioning Correlates and Differences Between Early and Adult Onset.
Puig O; Baeza I; de la Serna E; Cabrera B; Mezquida G; Bioque M; Lobo A; González-Pinto A; Parellada M; Corripio I; Vieta E; Bobes J; Usall J; Contreras F; Cuesta MJ; Bernardo M; Castro-Fornieles J;
J Clin Psychiatry; 2017; 78(9):1414-1422. PubMed ID: 28922588
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features.
Yung AR; Phillips LJ; Yuen HP; McGorry PD
Schizophr Res; 2004 Apr; 67(2-3):131-42. PubMed ID: 14984872
[TBL] [Abstract][Full Text] [Related]
7. The course of neurocognition and social functioning in individuals at ultra high risk for psychosis.
Niendam TA; Bearden CE; Zinberg J; Johnson JK; O'Brien M; Cannon TD
Schizophr Bull; 2007 May; 33(3):772-81. PubMed ID: 17420177
[TBL] [Abstract][Full Text] [Related]
8. Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning.
Bucci P; Mucci A; van Rossum IW; Aiello C; Arango C; Baandrup L; Buchanan RW; Dazzan P; Demjaha A; Díaz-Caneja CM; Giordano GM; Glenthøj BY; Leucht S; McGuire P; Rodriguez-Jimenez R; Vignapiano A; Kahn RS; Galderisi S
Eur Neuropsychopharmacol; 2020 May; 34():76-86. PubMed ID: 32291210
[TBL] [Abstract][Full Text] [Related]
9. Childhood maltreatment and transition to psychotic disorder independently predict long-term functioning in young people at ultra-high risk for psychosis.
Yung AR; Cotter J; Wood SJ; McGorry P; Thompson AD; Nelson B; Lin A
Psychol Med; 2015 Dec; 45(16):3453-65. PubMed ID: 26166153
[TBL] [Abstract][Full Text] [Related]
10. Persistent negative symptoms in youth at clinical high risk for psychosis: A longitudinal study.
Devoe DJ; Lu L; Cannon TD; Cadenhead KS; Cornblatt BA; McGlashan TH; Perkins DO; Seidman LJ; Tsuang MT; Woods SW; Walker EF; Mathalon DH; Bearden CE; Addington J
Schizophr Res; 2021 Jan; 227():28-37. PubMed ID: 32362460
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis.
Lin A; Wood SJ; Nelson B; Brewer WJ; Spiliotacopoulos D; Bruxner A; Broussard C; Pantelis C; Yung AR
Schizophr Res; 2011 Oct; 132(1):1-7. PubMed ID: 21763109
[TBL] [Abstract][Full Text] [Related]
12. Neurocognitive performance and functional disability in the psychosis prodrome.
Niendam TA; Bearden CE; Johnson JK; McKinley M; Loewy R; O'Brien M; Nuechterlein KH; Green MF; Cannon TD
Schizophr Res; 2006 May; 84(1):100-11. PubMed ID: 16563699
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive functioning of subjects with putative pre-psychotic states and early psychosis.
Liu CC; Hua MS; Hwang TJ; Chiu CY; Liu CM; Hsieh MH; Chien YL; Lin YT; Hwu HG
Schizophr Res; 2015 May; 164(1-3):40-6. PubMed ID: 25802138
[TBL] [Abstract][Full Text] [Related]
14. Identifying risk factors for predominant negative symptoms from early stages in schizophrenia: A longitudinal and sex-specific study in first-episode schizophrenia patients.
Mezquida G; Amoretti S; Bioque M; García-Rizo C; Sánchez-Torres AM; Pina-Camacho L; Lopez-Pena P; Mané A; Rodriguez-Jimenez R; Corripio I; Sarró S; Ibañez A; Usall J; García-Portilla MP; Vieta E; Mas S; Cuesta MJ; Parellada M; González-Pinto A; Berrocoso E; Bernardo M;
Span J Psychiatry Ment Health; 2023; 16(3):159-168. PubMed ID: 37716849
[TBL] [Abstract][Full Text] [Related]
15. Lack of insight 3 years after first-episode psychosis: an unchangeable illness trait determined from first presentation?
Ayesa-Arriola R; Moríñigo JD; David AS; Pérez-Iglesias R; Rodríguez-Sánchez JM; Crespo-Facorro B
Schizophr Res; 2014 Aug; 157(1-3):271-7. PubMed ID: 24934905
[TBL] [Abstract][Full Text] [Related]
16. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Galderisi S; Mucci A; Bitter I; Libiger J; Bucci P; Fleischhacker WW; Kahn RS;
Eur Neuropsychopharmacol; 2013 Mar; 23(3):196-204. PubMed ID: 22647933
[TBL] [Abstract][Full Text] [Related]
17. The history of childhood trauma among individuals with ultra high risk for psychosis is as common as among patients with first-episode schizophrenia.
Sahin S; Yüksel Ç; Güler J; Karadayı G; Akturan E; Göde E; Özhan AA; Üçok A
Early Interv Psychiatry; 2013 Nov; 7(4):414-20. PubMed ID: 23343404
[TBL] [Abstract][Full Text] [Related]
18. An investigation of a possible relationship between olfactory identification deficits at first episode and four-year outcomes in patients with psychosis.
Good KP; Tibbo P; Milliken H; Whitehorn D; Alexiadis M; Robertson N; Kopala LC
Schizophr Res; 2010 Dec; 124(1-3):60-5. PubMed ID: 20692126
[TBL] [Abstract][Full Text] [Related]
19. Impairment in verbal memory observed in first episode psychosis patients with persistent negative symptoms.
Hovington CL; Bodnar M; Joober R; Malla AK; Lepage M
Schizophr Res; 2013 Jul; 147(2-3):223-9. PubMed ID: 23628602
[TBL] [Abstract][Full Text] [Related]
20. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.
Korver N; Nieman DH; Becker HE; van de Fliert JR; Dingemans PH; de Haan L; Spiering M; Schmitz N; Linszen DH
Aust N Z J Psychiatry; 2010 Mar; 44(3):230-6. PubMed ID: 20180725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
